T-E Meds and Asymchem Laboratories successfully signed a strategic cooperation agreement. This partnership marks the beginning of a deep strategic collaboration in the field of innovative drug development, with the goal of jointly advancing the global pharmaceutical industry.

Ms. Yang Rui, Co-CEO of Asymchem, and Dr. Hsin-Mao Chu, CEO of T-E Meds, attended the signing ceremony and signed the agreement on behalf of both parties.

According to the strategic cooperation agreement, both parties will leverage their respective strengths in technology, R&D, manufacturing, and market access to carry out comprehensive strategic collaboration in the field of innovative drugs, particularly conjugated therapeutics. The scope of cooperation includes, but is not limited to, CDMO and clinical CRO services for multiple innovative drug candidates, such as antibody-drug conjugates (ADCs).

In addition, Asymchem will draw upon T-E Pharma’s powerful cytotoxic payload bundle platform to expand and enhance its conjugated drug toolbox capabilities, enabling a broader range of payload-linker combinations. This will allow ADC clients to achieve optimal efficacy while improving safety profiles.

Looking ahead, both parties will join hands to move forward, fully leveraging their respective strengths and integrating resources to explore the vast possibilities in the pharmaceutical field, contributing to the health and well-being of patients worldwide.